Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 20 March 1987:
Vol. 235. no. 4795, pp. 1492 - 1495
DOI: 10.1126/science.3103217
Prev | Table of Contents | Next

Articles

Science, Vol 235, Issue 4795, 1492-1495
Copyright © 1987 by American Association for the Advancement of Science

articles

Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes

JS Flier, MM Mueckler, P Usher, and HF Lodish

An accelerated rate of glucose transport is among the most characteristic biochemical markers of cellular transformation. To study the molecular mechanism by which transporter activity is altered, cultured rodent fibroblasts transfected with activated myc, ras, or src oncogenes were used. In myc-transfected cells, the rate of 2-deoxy-D-glucose uptake was unchanged. However, in cells transfected with activated ras and src oncogenes, the rate of glucose uptake was markedly increased. The increased transport rate in ras- and src-transfected cells was paralleled by a marked increase in the amount of glucose transporter protein, as assessed by immunoblots, as well as by a markedly increased abundance of glucose transporter messenger RNA. Exposure of control cells to the tumor-promoting phorbol ester 12-O-tetradecanoyl phorbol-13-acetate (TPA) for 18 hours had a similar effect of increasing the rate of glucose transport and the abundance of transporter messenger RNA. For ras, src, and TPA, the predominant mechanism responsible for activation of the transport system is increased expression of the structural gene encoding the glucose transport protein.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Glucose Deprivation Contributes to the Development of KRAS Pathway Mutations in Tumor Cells.
J. Yun, C. Rago, I. Cheong, R. Pagliarini, P. Angenendt, H. Rajagopalan, K. Schmidt, J. K. V. Willson, S. Markowitz, S. Zhou, et al. (2009)
Science 325, 1555-1559
   Abstract »    Full Text »    PDF »
Correlations between selected tumor markers and fluorodeoxyglucose maximal standardized uptake values in esophageal cancer.
M. D. Taylor, P. W. Smith, W. K. Brix, M. R. Wick, N. Theodosakis, B. R. Swenson, B. D. Kozower, and D. R. Jones (2009)
Eur. J. Cardiothorac. Surg. 35, 699-705
   Abstract »    Full Text »    PDF »
Fluorodeoxyglucose positron emission tomography and tumor marker expression in non-small cell lung cancer..
M. D. Taylor, P. W. Smith, W. K. Brix, M. R. Wick, N. Theodosakis, B. R. Swenson, B. D. Kozower, C. L. Lau, and D. R. Jones (2009)
J. Thorac. Cardiovasc. Surg. 137, 43-48
   Abstract »    Full Text »    PDF »
Transcriptional regulation of the insulin-responsive glucose transporter GLUT4 gene: from physiology to pathology.
E. Karnieli and M. Armoni (2008)
Am J Physiol Endocrinol Metab 295, E38-E45
   Abstract »    Full Text »    PDF »
Molecular Imaging of Metastatic Potential.
P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper (2008)
J. Nucl. Med. 49, 96S-112S
   Abstract »    Full Text »    PDF »
Hepatocyte Growth Factor Is a Novel Stimulator of Glucose Uptake and Metabolism in Skeletal Muscle Cells.
G. Perdomo, M. A. Martinez-Brocca, B. A. Bhatt, N. F. Brown, R. M. O'Doherty, and A. Garcia-Ocana (2008)
J. Biol. Chem. 283, 13700-13706
   Abstract »    Full Text »    PDF »
Enhancement of Glucose Transporter Expression of Brain Endothelial Cells by Vascular Endothelial Growth Factor Derived from Glioma Exposed to Hypoxia.
W.-L. Yeh, C.-J. Lin, and W.-M. Fu (2008)
Mol. Pharmacol. 73, 170-177
   Abstract »    Full Text »    PDF »
Imaging Gastric Cancer with PET and the Radiotracers 18F-FLT and 18F-FDG: A Comparative Analysis.
K. Herrmann, K. Ott, A. K. Buck, F. Lordick, D. Wilhelm, M. Souvatzoglou, K. Becker, T. Schuster, H.-J. Wester, J. R. Siewert, et al. (2007)
J. Nucl. Med. 48, 1945-1950
   Abstract »    Full Text »    PDF »
Ability of Positron Emission Tomography to Detect Residual Neck Node Disease in Patients With Head and Neck Squamous Cell Carcinoma After Definitive Chemoradiotherapy.
A. Tan, D. J. Adelstein, L. A. Rybicki, J. P. Saxton, R. M. Esclamado, B. G. Wood, R. R. Lorenz, M. Strome, and M. A. Carroll (2007)
Arch Otolaryngol Head Neck Surg 133, 435-440
   Abstract »    Full Text »    PDF »
Tumor hypoxia imaging..
I. Serganova, J. Humm, C. Ling, and R. Blasberg (2006)
Clin. Cancer Res. 12, 5260-5264
   Full Text »    PDF »
Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer.
H Furukawa, H Ikuma, A Seki, K Yokoe, S Yuen, T Aramaki, and S Yamagushi (2006)
Gut 55, 1007-1011
   Abstract »    Full Text »    PDF »
Therapeutic Effect of Imatinib in Gastrointestinal Stromal Tumors: AKT Signaling Dependent and Independent Mechanisms..
C. Tarn, Y. V. Skorobogatko, T. Taguchi, B. Eisenberg, M. von Mehren, and A. K. Godwin (2006)
Cancer Res. 66, 5477-5486
   Abstract »    Full Text »    PDF »
Phosphorylation of the 6-Phosphofructo-2-Kinase/Fructose 2,6-Bisphosphatase/PFKFB3 Family of Glycolytic Regulators in Human Cancer.
H. Bando, T. Atsumi, T. Nishio, H. Niwa, S. Mishima, C. Shimizu, N. Yoshioka, R. Bucala, and T. Koike (2005)
Clin. Cancer Res. 11, 5784-5792
   Abstract »    Full Text »    PDF »
Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras-Directed Therapy.
J. B. Fleming, G.-L. Shen, S. E. Holloway, M. Davis, and R. A. Brekken (2005)
Mol. Cancer Res. 3, 413-423
   Abstract »    Full Text »    PDF »
Functional Imaging in Lung Cancer.
L. K. Shankar and D. C. Sullivan (2005)
J. Clin. Oncol. 23, 3203-3211
   Abstract »    Full Text »    PDF »
Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements.
A. Ramanathan, C. Wang, and S. L. Schreiber (2005)
PNAS 102, 5992-5997
   Abstract »    Full Text »    PDF »
Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development.
G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. (2005)
Clin. Cancer Res. 11, 2785-2808
   Abstract »    Full Text »    PDF »
Biologic Correlates of Intratumoral Heterogeneity in 18F-FDG Distribution with Regional Expression of Glucose Transporters and Hexokinase-II in Experimental Tumor.
S. Zhao, Y. Kuge, T. Mochizuki, T. Takahashi, K. Nakada, M. Sato, T. Takei, and N. Tamaki (2005)
J. Nucl. Med. 46, 675-682
   Abstract »    Full Text »    PDF »
Differential Regulation of Phosphoglucose Isomerase/Autocrine Motility Factor Activities by Protein Kinase CK2 Phosphorylation.
T. Yanagawa, T. Funasaka, S. Tsutsumi, T. Raz, N. Tanaka, and A. Raz (2005)
J. Biol. Chem. 280, 10419-10426
   Abstract »    Full Text »    PDF »
Positherapy: Targeted Nuclear Therapy of Breast Cancer with 18F-2-Deoxy-2-Fluoro-D-Glucose.
R. M. Moadel, R. H. Weldon, E. B. Katz, P. Lu, J. Mani, M. Stahl, M. D. Blaufox, R. G. Pestell, M. J. Charron, and E. Dadachova (2005)
Cancer Res. 65, 698-702
   Abstract »    Full Text »    PDF »
Evaluation of the solitary pulmonary nodule: clinical management, role of CT and nuclear medicine.
D R Baldwin, J D Birchall, R H Ganatra, and K S Pointon (2004)
Imaging 16, 22-36
   Abstract »    Full Text »    PDF »
[18F]Fluoro-2-deoxy-D-glucose Positron Emission Tomography Detects Gastric Carcinoma in an Early Stage in an Asymptomatic E-Cadherin Mutation Carrier.
M. C. A. van Kouwen, J. P. H. Drenth, W. J. G. Oyen, J. H. F. M. de Bruin, M. J. Ligtenberg, J. J. (H. Bonenkamp, J. H. J. M. van Krieken, and F. M. Nagengast (2004)
Clin. Cancer Res. 10, 6456-6459
   Abstract »    Full Text »    PDF »
Seeking a Home for a PET, Part 1: Defining the Appropriate Place for Positron Emission Tomography Imaging in the Diagnosis of Pulmonary Nodules or Masses.
F. C. Detterbeck, S. Falen, M. P. Rivera, J. S. Halle, and M. A. Socinski (2004)
Chest 125, 2294-2299
   Abstract »    Full Text »    PDF »
The Tumor Suppressor p53 Down-Regulates Glucose Transporters GLUT1 and GLUT4 Gene Expression.
F. Schwartzenberg-Bar-Yoseph, M. Armoni, and E. Karnieli (2004)
Cancer Res. 64, 2627-2633
   Abstract »    Full Text »    PDF »
2-Deoxy-D-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo.
G. Maschek, N. Savaraj, W. Priebe, P. Braunschweiger, K. Hamilton, G. F. Tidmarsh, L. R. De Young, and T. J. Lampidis (2004)
Cancer Res. 64, 31-34
   Abstract »    Full Text »    PDF »
18F-FDG Uptake in Squamous Cell Carcinoma of the Cervix Is Correlated with Glucose Transporter 1 Expression.
T.-C. Yen, L.-C. See, C.-H. Lai, C. W. Yah-Huei, K.-K. Ng, S.-Y. Ma, W.-J. Lin, J.-T. Chen, W.-J. Chen, C.-R. Lai, et al. (2004)
J. Nucl. Med. 45, 22-29
   Abstract »    Full Text »    PDF »
Implications of Glucose Transporter Protein Type 1 (GLUT1)-Haplodeficiency in Embryonic Stem Cells for Their Survival in Response to Hypoxic Stress.
C. Heilig, F. Brosius, B. Siu, L. Concepcion, R. Mortensen, K. Heilig, M. Zhu, R. Weldon, G. Wu, and D. Conner (2003)
Am. J. Pathol. 163, 1873-1885
   Abstract »    Full Text »    PDF »
Prospective Comparison of 18F-FDG PET with Conventional Imaging Modalities (MRI, CT, and 67Ga Scintigraphy) in Assessment of Combined Intraarterial Chemotherapy and Radiotherapy for Head and Neck Carcinoma.
Y. Kitagawa, S. Nishizawa, K. Sano, T. Ogasawara, M. Nakamura, N. Sadato, M. Yoshida, and Y. Yonekura (2003)
J. Nucl. Med. 44, 198-206
   Abstract »    Full Text »    PDF »
11C-Acetate: A New Tracer for the Evaluation of Hepatocellular Carcinoma.
D. Delbeke and C. W. Pinson (2003)
J. Nucl. Med. 44, 222-223
   Full Text »    PDF »
PAX3/Forkhead Homolog in Rhabdomyosarcoma Oncoprotein Activates Glucose Transporter 4 Gene Expression in Vivo and in Vitro.
M. Armoni, M. J. Quon, G. Maor, S. Avigad, D. N. Shapiro, C. Harel, D. Esposito, Y. Goshen, I. Yaniv, and E. Karnieli (2002)
J. Clin. Endocrinol. Metab. 87, 5312-5324
   Abstract »    Full Text »    PDF »
Solitary Pulmonary Nodules: Potential Role of Dynamic MR Imaging in Management—Initial Experience.
Y. Ohno, H. Hatabu, D. Takenaka, S. Adachi, M. Kono, and K. Sugimura (2002)
Radiology 224, 503-511
   Abstract »    Full Text »    PDF »
Coexpression of Glucose Transporter 1 and Matrix Metalloproteinase-2 in Human Cancers.
S. Ito, T. Fukusato, T. Nemoto, H. Sekihara, Y. Seyama, and S. Kubota (2002)
J Natl Cancer Inst 94, 1080-1091
   Abstract »    Full Text »    PDF »
Hypoxia-inducible Factor 1 Activation by Aerobic Glycolysis Implicates the Warburg Effect in Carcinogenesis.
H. Lu, R. A. Forbes, and A. Verma (2002)
J. Biol. Chem. 277, 23111-23115
   Abstract »    Full Text »    PDF »
The Impact of PET on the Management of Lung Cancer: The Referring Physician's Perspective.
M. A. Seltzer, C. S. Yap, D. H. Silverman, J. Meta, C. Schiepers, M. E. Phelps, S. S. Gambhir, J. Rao, P. E. Valk, and J. Czernin (2002)
J. Nucl. Med. 43, 752-756
   Abstract »    Full Text »    PDF »
FDG Uptake and Glucose Transporter Subtype Expressions in Experimental Tumor and Inflammation Models.
T. Mochizuki, E. Tsukamoto, Y. Kuge, K. Kanegae, S. Zhao, K. Hikosaka, M. Hosokawa, M. Kohanawa, and N. Tamaki (2001)
J. Nucl. Med. 42, 1551-1555
   Abstract »    Full Text »    PDF »
Dual Time Point 18F-FDG PET Imaging for Differentiating Malignant from Inflammatory Processes.
H. Zhuang, M. Pourdehnad, E. S. Lambright, A. J. Yamamoto, M. Lanuti, P. Li, P. D. Mozley, M. D. Rossman, S. M. Albelda, and A. Alavi (2001)
J. Nucl. Med. 42, 1412-1417
   Abstract »    Full Text »    PDF »
VHL tumor suppressor regulates Cl-/HCO3- exchange and Na+/H+ exchange activities in renal carcinoma cells.
S. A. KARUMANCHI, L. JIANG, B. KNEBELMANN, A. K. STUART-TILLEY, S. L. ALPER, and V. P. SUKHATME (2001)
Physiol Genomics 5, 119-128
   Abstract »    Full Text »    PDF »
Glucose Metabolism of Breast Cancer Assessed by 18F-FDG PET: Histologic and Immunohistochemical Tissue Analysis.
N. Avril, M. Menzel, J. Dose, M. Schelling, W. Weber, F. Janicke, W. Nathrath, and M. Schwaiger (2001)
J. Nucl. Med. 42, 9-16
   Abstract »    Full Text »    PDF »
Glucose transporters and transport kinetics in retinoic acid-differentiated T47D human breast cancer cells.
D. Rivenzon-Segal, E. Rushkin, S. Polak-Charcon, and H. Degani (2000)
Am J Physiol Endocrinol Metab 279, E508-E519
   Abstract »    Full Text »    PDF »
Surveillance for Recurrent Head and Neck Cancer Using Positron Emission Tomography.
V. J. Lowe, J. H. Boyd, F. R. Dunphy, H. Kim, T. Dunleavy, B. T. Collins, D. Martin, B. C. Stack Jr, C. Hollenbeak, and J. W. Fletcher (2000)
J. Clin. Oncol. 18, 651
   Abstract »    Full Text »    PDF »
Primary and Recurrent Early Stage Laryngeal Cancer: Preliminary Results of 2-[Fluorine 18]fluoro-2-deoxy-D-glucose PET Imaging.
V. J. Lowe, H. Kim, J. H. Boyd, J. F. Eisenbeis, F. R. Dunphy, and J. W. Fletcher (1999)
Radiology 212, 799-802
   Abstract »    Full Text »
Regulation of GLUT1 Gene Transcription by the Serine/Threonine Kinase Akt1.
A. Barthel, S. T. Okino, J. Liao, K. Nakatani, J. Li, J. P. Whitlock Jr., and R. A. Roth (1999)
J. Biol. Chem. 274, 20281-20286
   Abstract »    Full Text »    PDF »
Evaluation of Benign vs Malignant Hepatic Lesions With Positron Emission Tomography.
D. Delbeke, W. H. Martin, M. P. Sandler, W. C. Chapman, J. K. Wright Jr, and C. W. Pinson (1998)
Arch Surg 133, 510-516
   Abstract »    Full Text »    PDF »
Role of the GLUT 2 Glucose Transporter in the Response of the L-type Pyruvate Kinase Gene to Glucose in Liver-derived Cells.
B. Antoine, A.-M. Lefrancois-Martinez, G. Le Guillou, A. Leturque, A. Vandewalle, and A. Kahn (1997)
J. Biol. Chem. 272, 17937-17943
   Abstract »    Full Text »    PDF »
Increased Uptake and Accumulation of Vitamin C in Human Immunodeficiency Virus 1-infected Hematopoietic Cell Lines.
C. I. Rivas, J. C. Vera, V. H. Guaiquil, F. V. Velasquez, O. A. Borquez-Ojeda, J. G. Carcamo, I. I. Concha, and D. W. Golde (1997)
J. Biol. Chem. 272, 5814-5820
   Abstract »    Full Text »    PDF »
Genistein Is a Natural Inhibitor of Hexose and Dehydroascorbic Acid Transport through the Glucose Transporter, GLUT1.
J. C. Vera, A. M. Reyes, J. G. Cárcamo, F. V. Velásquez, C. I. Rivas, R. H. Zhang, P. Strobel, R. Iribarren, H. I. Scher, J. C. Slebe, et al. (1996)
J. Biol. Chem. 271, 8719-8724
   Abstract »    Full Text »    PDF »
A tumor-associated glycosylation change in the glucose transporter GLUT1 controlled by tumor suppressor function in human cell hybrids.
T Kitagawa, Y Tsuruhara, M Hayashi, T Endo, and E. Stanbridge (1995)
J. Cell Sci. 108, 3735-3743
   Abstract »    PDF »
Diabetic hyperglycemia: link to impaired glucose transport in pancreatic beta cells.
R. Unger (1991)
Science 251, 1200-1205
   Abstract »    PDF »
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc.
R. C. Osthus, H. Shim, S. Kim, Q. Li, R. Reddy, M. Mukherjee, Y. Xu, D. Wonsey, L. A. Lee, and C. V. Dang (2000)
J. Biol. Chem. 275, 21797-21800
   Abstract »    Full Text »    PDF »
Identification of a Novel Ligand-Receptor Pair Constitutively Activated by ras Oncogenes.
R. Zhang, Z. Tan, and P. Liang (2000)
J. Biol. Chem. 275, 24436-24443
   Abstract »    Full Text »    PDF »
Regulation of glut1 mRNA by Hypoxia-inducible Factor-1. INTERACTION BETWEEN H-ras AND HYPOXIA.
C. Chen, N. Pore, A. Behrooz, F. Ismail-Beigi, and A. Maity (2001)
J. Biol. Chem. 276, 9519-9525
   Abstract »    Full Text »    PDF »
MKK6/3 and p38 MAPK Pathway Activation Is Not Necessary for Insulin-induced Glucose Uptake but Regulates Glucose Transporter Expression.
M. Fujishiro, Y. Gotoh, H. Katagiri, H. Sakoda, T. Ogihara, M. Anai, Y. Onishi, H. Ono, M. Funaki, K. Inukai, et al. (2001)
J. Biol. Chem. 276, 19800-19806
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)